A drug for the treatment of breast cancer with an effectiveness of 72%

0
22


  Breast Cancer Awareness (Mustafa Hassouna / Anadolu Agency)</p><div><p dir="RTL" style="text-align:justify; margin-bottom:11px">The Swedish-British Pharmaceutical Company announced:<a target="_blank" href="https://www.alaraby.co.uk/society/%D9%86%D8%AA%D8%A7%D8%A6%D8%AC-%D9%85%D8%B4%D8%AC%D8%B9%D8%A9-%D9%84%D8%B9%D9%82%D8%A7%D8%B1-%D8%B7%D9%88%D8%B1%D8%AA%D9%87-%D8%A3%D8%B3%D8%AA%D8%B1%D8%A7%D8%B2%D9%8A%D9%86%D9%8A%D9%83%D8%A7-%D9%8A%D8%AD%D8%AF%D9%91-%D9%85%D9%86-%D8%A7%D9%84%D8%A3%D8%B4%D9%83%D8%A7%D9%84-%D8%A7%D9%84%D8%AD%D8%A7%D8%AF%D8%A9-%D9%85%D9%86-%D9%83%D9%88%D8%B1%D9%88%D9%86%D8%A7" rel="noopener">AstraZeneca</a>Development of a new drug to treat <a target="_blank" href="https://www.alaraby.co.uk/society/%D9%85%D8%A8%D8%A7%D8%AF%D8%B1%D8%A9-%D8%A8%D8%AD%D8%AB%D9%8A%D8%A9%C2%A0%D9%84%D9%83%D8%B4%D9%81-%D8%AC%D9%8A%D9%86%D8%A7%D8%AA-%D8%B3%D8%B1%D8%B7%D8%A7%D9%86-%D8%A7%D9%84%D8%AB%D8%AF%D9%8A-%D9%84%D8%AF%D9%89-%D8%A7%D9%84%D8%B9%D8%B1%D8%A8" rel="noopener">breast cancer</a>It would reduce the risk of death or disease progression by 72 percent compared to the current treatment.

According to the company’s website, the results of studies conducted during the last period showed that Enhertu has the ability to save patients’ lives. The study’s authors named Destiny-Breast03 for their findings, which were published during a European medical conference.

How was the experience?

The third phase of treatment was concluded after about 500 patients in different places in Asia, Europe, North and South America underwent the drug developed by the company. It was compared with the standard treatment “trastuzumab emtancin” for the treatment of breast cancer patients to compare the results.

It was found that 94 per cent of patients treated with the British Swedish drug managed to survive, compared to 85 per cent for patients who were treated with other drugs.

“Today’s results are groundbreaking,” said Susan Galbraith, executive vice president of research and development in oncology at AstraZeneca, especially since nearly all patients treated with the new drug had no side effects.

What is ENHERTU treatment?

ENHERTU medicine is prepared from pharmaceutical Which treat cancerous diseases, especially breast cancer that cannot be removed by surgery or that has metastasized to other parts of the body. The US Food and Drug Administration has approved ENHERTU Based on a clinical study that measures the number of patients who responded and how long they responded.

So far, it is not known whether the drug is safe and effective for childhood cancers, according to the brand’s website.

What are the advantages of treatment?

The new treatment has the advantage of fighting the possibility of cancer recurring, according to Javier Cortes of the International Breast Cancer Center in Barcelona. “Usually, patients who develop HER2-positive breast cancer typically have disease progression in less than a year with available targeted therapies to treat this type of cancer,” he says. But with the new drug, the extent of the disease has been shown to remain constant, with some patients even Those treated did not develop cancer again.

flag stand

Breast Cancer UK, which provides support and information about the disease, welcomed the trial results as “incredibly promising”. “It is fantastic to see a drug that can give hundreds of people with incurable HER2-positive breast cancer a chance for more time before their disease progresses,” said Corretna Timsenati, Senior Director of Research Communications.

“We are now hopeful that more research will show whether this treatment can also provide patients with valuable extra time to live and survive in more important moments,” she adds.

commercial purposes?

Analysts have estimated that Enhertu’s sales will reach $500 million in a short period of time, and these numbers remain the subject of deep future studies by global medical institutions. According to the Fierce Pharma website It is based in the United States of America, and many question marks will be present in the coming period, as it is likely that drug industry observers will continue to research the side effects of the drug to evaluate it before it is finally launched.

However, Dave Frederickson, head of the oncology business unit at AstraZeneca, indicated in an interview on the brand’s website, that studies conducted on the drug did not prove that any patient had any of the fourth or fifth side effects, which are very dangerous symptoms. The results proved that the symptoms were not beyond delirium, or headache.





LEAVE A REPLY

Please enter your comment!
Please enter your name here